Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Ontology highlight
ABSTRACT: Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults and is universally fatal. The DNA alkylating agent temozolomide is part of the standard-of-care for GBM. However, these tumors eventually develop therapy-driven resistance and inevitably recur. While loss of mismatch repair (MMR) and re-expression of MGMT have been shown to underlie chemoresistance in a fraction of GBMs, resistance mechanisms operating in the remaining GBMs are not well understood. To better understand the molecular basis for therapy-driven temozolomide resistance, mice bearing orthotopic GBM xenografts were subjected to protracted temozolomide treatment, and cell lines were generated from the primary (untreated) and recurrent (temozolomide-treated) tumors. As expected, the cells derived fro
SUBMITTER: Gil Del Alcazar CR
PROVIDER: S-EPMC5065752 | biostudies-literature | 2016 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA